Harald Reinhart - 01 Apr 2024 Form 4 Insider Report for Zai Lab Ltd (ZLAB)

Role
President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
Signature
/s/ Bruce Blefeld, Attorney-in-Fact
Issuer symbol
ZLAB
Transactions as of
01 Apr 2024
Net transactions value
+$44,063
Form type
4
Filing time
03 Apr 2024, 21:45:08 UTC
Previous filing
03 Jan 2024
Next filing
05 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZLAB American Depositary Shares Options Exercise $55,811 +3,338 +7.2% $16.72 49,398 01 Apr 2024 Direct F1, F2
transaction ZLAB American Depositary Shares Options Exercise $16,887 +1,010 +2% $16.72 50,408 01 Apr 2024 Direct F1, F2
transaction ZLAB American Depositary Shares Sale $21,965 -1,360 -2.7% $16.15 49,048 02 Apr 2024 Direct F1, F3
transaction ZLAB American Depositary Shares Sale $6,670 -413 -0.84% $16.15 48,635 02 Apr 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZLAB Stock Options (Right to Buy) Award $0 +107,321 $0.000000 107,321 01 Apr 2024 American Depositary Shares 107,321 $16.72 Direct F1, F4, F5
transaction ZLAB Restricted Share Units Award $0 +69,758 $0.000000 69,758 01 Apr 2024 American Depositary Shares 69,758 Direct F1, F6, F7
transaction ZLAB Restricted Share Units Options Exercise $0 -3,338 -25% $0.000000 10,016 01 Apr 2024 American Depositary Shares 3,338 Direct F1, F6, F8
transaction ZLAB Restricted Share Units Options Exercise $0 -1,010 -33% $0.000000 2,020 01 Apr 2024 American Depositary Shares 1,010 Direct F1, F6, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2 ADSs acquired on vesting of Restricted Share Units.
F3 These ADSs were sold automatically to cover taxes upon vesting of Restricted Share Units.
F4 Each Stock Option is exercisable for one ADS, which represents ten Ordinary Shares of the issuer.
F5 The option vests in equal annual installments over four years beginning on 04/01/2025, the first anniversary of the date of grant, subject to continuous service.
F6 Each Restricted Share Unit ("RSU") represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer.
F7 The RSUs vest in equal annual installments over four years beginning on 04/01/2025, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered to the reporting person following vesting.
F8 The RSUs vest in equal annual installments over five years beginning on 04/01/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.
F9 The RSUs vest in equal annual installments over five years beginning on 04/01/2022, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.

Remarks:

President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases